|
Metastatic Breast Cancer – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 353 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Metastatic Breast Cancer - Pipeline Review, H1 2012', provides an overview of the Metastatic Breast Cancer therapeutic pipeline. This report provides informatio.....
Introduction Global Markets Direct’s, 'Metastatic Breast Cancer - Pipeline Review, H1 2012', provides an overview of the Metastatic Breast Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer. 'Metastatic Breast Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Metastatic Breast Cancer. - A review of the Metastatic Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Breast Cancer pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Metastatic Breast Cancer therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 11 Introduction 12 Global Markets Direct Report Coverage 12 Metastatic Breast Cancer Overview 13 Therapeutics Development 14 An Overview of Pipeline Products for Metastatic Breast Cancer 14 Metastatic Breast Cancer Therapeutics under Development by Companies 16 Metastatic Breast Cancer Therapeutics under Investigation by Universities/Institutes 22 Late Stage Products 37 Comparative Analysis 37 Mid Clinical Stage Products 38 Comparative Analysis 38 Early Clinical Stage Products 39 Comparative Analysis 39 Discovery and Pre-Clinical Stage Products 40 Comparative Analysis 40 Metastatic Breast Cancer Therapeutics – Products under Development by Companies 41 Metastatic Breast Cancer Therapeutics – Products under Investigation by Universities/Institutes 51 Companies Involved in Metastatic Breast Cancer Therapeutics Development 82 Bristol-Myers Squibb Company 82 Boehringer Ingelheim GmbH 83 F. Hoffmann-La Roche Ltd. 84 Kyowa Hakko Kirin Co., Ltd. 85 Abbott Laboratories 86 Biogen Idec Inc. 87 Amgen Inc. 88 Sanofi-Aventis 89 Adherex Technologies Inc. 90 AstraZeneca PLC 91 Eli Lilly and Company 92 GlaxoSmithKline plc 93 Genentech, Inc. 94 Nektar Therapeutics 95 Daiichi Sankyo Company, Ltd 96 Infinity Pharmaceuticals, Inc. 97 ZIOPHARM Oncology, Inc. 98 Millennium Pharmaceuticals, Inc. 99 Novartis AG 100 ImClone Systems Incorporated 101 Astellas Pharma Inc. 102 Eisai Co., Ltd. 103 Genta Incorporated 104 Nippon Kayaku Co., Ltd. 105 Pfizer Inc. 106 Taiho Pharmaceutical Co., Ltd. 107 Teva Pharmaceutical Industries Limited 108 Cell Therapeutics, Inc. 109 Enzon Pharmaceuticals, Inc. 110 Celgene Corporation 111 Bayer AG 112 Incyte Corporation 113 Geron Corporation 114 Merck KGaA 115 EntreMed, Inc. 116 Celldex Therapeutics, Inc. 117 Cougar Biotechnology, Inc. 118 Peregrine Pharmaceuticals, Inc. 119 Allos Therapeutics, Inc 120 Bionovo, Inc. 121 Cytokinetics, Inc 122 Telik, Inc. 123 Array BioPharma Inc. 124 Natco Pharma Limited 125 Piramal Life Sciences Limited 126 Wilex AG 127 TRION Pharma GmbH 128 BioNumerik Pharmaceuticals, Inc. 129 Cytheris SA 130 Quantum Immunologics, Inc. 131 PTC Therapeutics, Inc. 132 Immutep S.A. 133 Syndax Pharmaceuticals, Inc. 134 BiPar Sciences, Inc. 135 NewLink Genetics Corporation 136 Sopherion Therapeutics, LLC 137 AVEO Pharmaceuticals, Inc. 138 TRACON Pharmaceuticals, Inc. 139 Merus B.V. 140 Aragon Pharmaceuticals, Inc. 141 Oncozyme Pharma Inc. 142 Metastatic Breast Cancer – Therapeutics Assessment 143 Assessment by Monotherapy Products 143 Assessment by Combination Products 144 Assessment by Route of Administration 145 Assessment by Molecule Type 148 Drug Profiles 151 Halaven - Drug Profile 151 SNDX 275 - Drug Profile 152 RG3502 - Drug Profile 154 Pertuzumab - Drug Profile 155 NKTR-102 - Drug Profile 156 Tavocept - Drug Profile 158 Avastin - Drug Profile 160 Afinitor - Drug Profile 162 BSI-201 - Drug Profile 164 IMC-1121B - Drug Profile 166 Herceptin + Radiation Therapy - Drug Profile 168 Anastrozole + Fulvestrant - Drug Profile 169 Herceptin + Navelbine - Drug Profile 170 FEC Chemotherapy + Docetaxel - Drug Profile 171 FEC Chemotherapy + DG Chemotherapy - Drug Profile 173 Fulvestrant. - Drug Profile 175 Fulvestrant + Exemestane + Anastrozole + Letrozole - Drug Profile 176 Fulvestrant + Lapatinib - Drug Profile 178 Faslodex + Arimidex - Drug Profile 180 Faslodex - Drug Profile 182 Exemestane - Drug Profile 183 Taxol - Drug Profile 185 Gemcitabine + Vinorelbine - Drug Profile 187 Capecitabine - Drug Profile 188 Bevacizumab + Paclitaxel - Drug Profile 189 Bevacizumab + Paclitaxel Albumin-Stabilized Nanoparticle Formulation - Drug Profile 190 Bevacizumab + Ixabepilone - Drug Profile 191 Bevacizumab + Capecitabine - Drug Profile 192 Capecitabine - Drug Profile 193 Vinorelbine + Trastuzumab - Drug Profile 194 Marimastat - Drug Profile 196 Carboplatin + Paclitaxel + Trastuzumab + Bevacizumab - Drug Profile 197 Imatinib + Vinorelbine - Drug Profile 199 Afinitor + Exemestane - Drug Profile 200 Everolimus + Trastuzumab + Vinorelbine - Drug Profile 201 Tykerb + Paclitaxel - Drug Profile 203 BSI-201 + Gemcitabine + Carboplatin - Drug Profile 204 Docetaxel + Vitamin D2 - Drug Profile 206 Herceptin + Taxol - Drug Profile 207 Paclitaxel + Trastuzumab + GW572016 - Drug Profile 208 Avastin + Xeloda - Drug Profile 210 Irinotecan + 5-Fluorouracil + Leucovorin + Bevacizumab - Drug Profile 212 Avastin + Herceptin + Docetaxel - Drug Profile 214 Herceptin + Avastin - Drug Profile 216 Pertuzumab + Herceptin + Docetaxel - Drug Profile 217 Pertuzumab + Herceptin - Drug Profile 219 Avastin + Taxane - Drug Profile 221 Zoledronic Acid - Drug Profile 223 Herceptin - Drug Profile 224 Bevacizumab + Letrozole - Drug Profile 225 Docetaxel + Gemcitabine - Drug Profile 226 Aromasin + Celebrex - Drug Profile 227 Adiramycin + Cyclophosphamide + Docetaxel - Drug Profile 228 Bevacizumab + Paclitaxel - Drug Profile 229 Tamoxifen - Drug Profile 230 Taxotere + Epirubicin - Drug Profile 231 Navelbine + Taxotere - Drug Profile 232 Paclitaxel - Drug Profile 233 Epirubicin + Cyclophosphamide + 5-Fuorouracil - Drug Profile 234 Myocet + Taxol + Herceptin - Drug Profile 236 Trastuzumab-DM1 + Pertuzumab - Drug Profile 237 Theratope Vaccine + Detox - Drug Profile 239 Paclitaxel/Docetaxel + Lapatinib - Drug Profile 240 Lapatinib + Trastuzumab + Letrozole - Drug Profile 242 Docetaxel - Drug Profile 244 TS-1 - Drug Profile 245 Eribulin Mesylate - Drug Profile 246 IMC-1121B + Docetaxel - Drug Profile 247 Lapatinib + Trastuzumab + Anastrozole - Drug Profile 249 Lapatinib + Trastuzumab + Exemestane - Drug Profile 251 S-1 - Drug Profile 253 Doxorubicin + Docetaxel - Drug Profile 254 Doxorubicin + Paclitaxel - Drug Profile 255 Epirubicin + Cyclophosphamide - Drug Profile 256 Epirubicin + Docetaxel - Drug Profile 257 Epirubicin Hydrochloride + Paclitaxel - Drug Profile 258 Filgrastim + Carmustine + Cisplatin + Cyclophosphamide + Etoposide + Thiotepa + Peripheral Blood Stem Cell Transplantation - Drug Profile 259 Cyclophosphamide + Epirubicin - Drug Profile 261 5-Fluorouracil + Leucovorin + Adriamycin + Cytoxan + Granulocyte-Macrophage Colony-Stimulating Factor - Drug Profile 263 Docetaxel + Epirubicin + Cyclophosphamide + 5-Fluoruracil + Granulocyte-Colony Stimulating Growth Factor - Drug Profile 265 Docetaxel + Epirubicin + Cyclophosphamide + 5-Fluoruracil + Trastuzumab + Granulocyte-Colony Stimulating Growth Factor - Drug Profile 268 Filgrastim + Cyclophosphamide + Epirubicin hydrochloride + Fluorouracil + Thiotepa - Drug Profile 271 Bevacizumab + Capecitabine + Cyclophosphamide + Paclitaxel - Drug Profile 273 Capecitabine - Drug Profile 276 Aromasin + Entinostat - Drug Profile 277 Avastin + Docetaxel - Drug Profile 278 RAD001 + Trastuzumab + Paclitaxel - Drug Profile 280 Docetaxel + Pertuzumab + Trastuzumab - Drug Profile 282 Bevacizumab + Exemestane - Drug Profile 284 Bevacizumab + Fulvestrant - Drug Profile 285 Gemcitabine + Docetaxel - Drug Profile 286 Capecitabine + Docetaxel - Drug Profile 288 Avastin + Standard Chemotherapy - Drug Profile 290 Bevacizumab + Docetaxel - Drug Profile 292 Metastatic Breast Cancer Therapeutics – Drug Profile Updates 293 Metastatic Breast Cancer Therapeutics – Discontinued Products 311 Metastatic Breast Cancer Therapeutics - Dormant Products 317 Metastatic Breast Cancer – Product Development Milestones 336 Featured News & Press Releases 336 Appendix 346 Methodology 346 Expert Panel Validation 347 Contact Us 347 Disclaimer 347 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Metastatic Breast Cancer, H1 2012 20 Products under Development for Metastatic Breast Cancer – Comparative Analysis, H1 2012 21 Number of Products under Development by Companies, H1 2012 23 Number of Products under Development by Companies, H1 2012 (Contd..1) 24 Number of Products under Development by Companies, H1 2012 (Contd..2) 25 Number of Products under Development by Companies, H1 2012 (Contd..3) 26 Number of Products under Development by Companies, H1 2012 (Contd..4) 27 Number of Products under Investigation by Universities/Institutes, H1 2012 29 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 30 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 31 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 32 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 33 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 34 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 35 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 36 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 37 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 38 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 39 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 40 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 41 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 42 Comparative Analysis by Late Stage Development, H1 2012 43 Comparative Analysis by Mid Clinical Stage Development, H1 2012 44 Comparative Analysis by Early Clinical Stage Development, H1 2012 45 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 46 Products under Development by Companies, H1 2012 47 Products under Development by Companies, H1 2012 (Contd..1) 48 Products under Development by Companies, H1 2012 (Contd..2) 49 Products under Development by Companies, H1 2012 (Contd..3) 50 Products under Development by Companies, H1 2012 (Contd..4) 51 Products under Development by Companies, H1 2012 (Contd..5) 52 Products under Development by Companies, H1 2012 (Contd..6) 53 Products under Development by Companies, H1 2012 (Contd..7) 54 Products under Development by Companies, H1 2012 (Contd..8) 55 Products under Development by Companies, H1 2012 (Contd..9) 56 Products under Investigation by Universities/Institutes, H1 2012 57 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 58 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 59 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 60 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 61 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 62 Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 63 Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 64 Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 65 Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 66 Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 67 Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 68 Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 69 Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 70 Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 71 Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 72 Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 73 Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 74 Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 75 Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 76 Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 77 Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 78 Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 79 Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 80 Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 81 Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 82 Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 83 Products under Investigation by Universities/Institutes, H1 2012 (Contd..27) 84 Products under Investigation by Universities/Institutes, H1 2012 (Contd..28) 85 Products under Investigation by Universities/Institutes, H1 2012 (Contd..29) 86 Products under Investigation by Universities/Institutes, H1 2012 (Contd..30) 87 Bristol-Myers Squibb Company, H1 2012 88 Boehringer Ingelheim GmbH, H1 2012 89 F. Hoffmann-La Roche Ltd., H1 2012 90 Kyowa Hakko Kirin Co., Ltd., H1 2012 91 Abbott Laboratories, H1 2012 92 Biogen Idec Inc., H1 2012 93 Amgen Inc., H1 2012 94 Sanofi-Aventis, H1 2012 95 Adherex Technologies Inc., H1 2012 96 AstraZeneca PLC, H1 2012 97 Eli Lilly and Company, H1 2012 98 GlaxoSmithKline plc, H1 2012 99 Genentech, Inc., H1 2012 100 Nektar Therapeutics, H1 2012 101 Daiichi Sankyo Company, Ltd, H1 2012 102 Infinity Pharmaceuticals, Inc., H1 2012 103 ZIOPHARM Oncology, Inc., H1 2012 104 Millennium Pharmaceuticals, Inc., H1 2012 105 Novartis AG, H1 2012 106 ImClone Systems Incorporated, H1 2012 107 Astellas Pharma Inc., H1 2012 108 Eisai Co., Ltd., H1 2012 109 Genta Incorporated, H1 2012 110 Nippon Kayaku Co., Ltd., H1 2012 111 Pfizer Inc., H1 2012 112 Taiho Pharmaceutical Co., Ltd., H1 2012 113 Teva Pharmaceutical Industries Limited, H1 2012 114 Cell Therapeutics, Inc., H1 2012 115 Enzon Pharmaceuticals, Inc., H1 2012 116 Celgene Corporation, H1 2012 117 Bayer AG, H1 2012 118 Incyte Corporation, H1 2012 119 Geron Corporation, H1 2012 120 Merck KGaA, H1 2012 121 EntreMed, Inc., H1 2012 122 Celldex Therapeutics, Inc., H1 2012 123 Cougar Biotechnology, Inc., H1 2012 124 Peregrine Pharmaceuticals, Inc., H1 2012 125 Allos Therapeutics, Inc, H1 2012 126 Bionovo, Inc., H1 2012 127 Cytokinetics, Inc, H1 2012 128 Telik, Inc., H1 2012 129 Array BioPharma Inc., H1 2012 130 Natco Pharma Limited, H1 2012 131 Piramal Life Sciences Limited, H1 2012 132 Wilex AG, H1 2012 133 TRION Pharma GmbH, H1 2012 134 BioNumerik Pharmaceuticals, Inc., H1 2012 135 Cytheris SA, H1 2012 136 Quantum Immunologics, Inc., H1 2012 137 PTC Therapeutics, Inc., H1 2012 138 Immutep S.A., H1 2012 139 Syndax Pharmaceuticals, Inc., H1 2012 140 BiPar Sciences, Inc., H1 2012 141 NewLink Genetics Corporation, H1 2012 142 Sopherion Therapeutics, LLC, H1 2012 143 AVEO Pharmaceuticals, Inc., H1 2012 144 TRACON Pharmaceuticals, Inc., H1 2012 145 Merus B.V., H1 2012 146 Aragon Pharmaceuticals, Inc., H1 2012 147 Oncozyme Pharma Inc., H1 2012 148 Assessment by Monotherapy Products, H1 2012 149 Assessment by Combination Products, H1 2012 150 Assessment by Stage and Route of Administration, H1 2012 153 Assessment by Molecule Type, H1 2012 156 Metastatic Breast Cancer Therapeutics – Drug Profile Updates 299 Metastatic Breast Cancer Therapeutics – Discontinued Products 317 Metastatic Breast Cancer Therapeutics – Discontinued Products (Contd..1) 318 Metastatic Breast Cancer Therapeutics – Discontinued Products (Contd..2) 319 Metastatic Breast Cancer Therapeutics – Discontinued Products (Contd..3) 320 Metastatic Breast Cancer Therapeutics – Discontinued Products (Contd..4) 321 Metastatic Breast Cancer Therapeutics – Discontinued Products (Contd..5) 322 Metastatic Breast Cancer Therapeutics – Dormant Products 323 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..1) 324 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..2) 325 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..3) 326 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..4) 327 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..5) 328 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..6) 329 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..7) 330 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..8) 331 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..9) 332 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..10) 333 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..11) 334 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..12) 335 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..13) 336 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..14) 337 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..15) 338 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..16) 339 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..17) 340 Metastatic Breast Cancer Therapeutics – Dormant Products (Contd..18) 341 List of Figures Number of Products under Development for Metastatic Breast Cancer, H1 2012 20 Products under Development for Metastatic Breast Cancer – Comparative Analysis, H1 2012 21 Products under Development by Companies, H1 2012 22 Products under Investigation by Universities/Institutes, H1 2012 28 Late Stage Products, H1 2012 43 Mid Clinical Stage Products, H1 2012 44 Early Clinical Stage Products, H1 2012 45 Discovery and Pre-Clinical Stage Products, H1 2012 46 Assessment by Monotherapy Products, H1 2012 149 Assessment by Combination Products, H1 2012 150 Assessment by Route of Administration, H1 2012 151 Assessment by Stage and Route of Administration, H1 2012 152 Assessment by Molecule Type, H1 2012 154 Assessment by Stage and Molecule Type, H1 2012 155 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
